Castle Biosciences, Inc. - Common stock (CSTL)
Healthcare › Services-Medical Laboratories
Price History
Feb 9, 2026 — Aug 21, 2026Investment Snapshot
- Trading 28% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -2.7%
Castle Biosciences, Inc. - Common stock (CSTL) is a Healthcare company operating in Services-Medical Laboratories, listed on the NASDAQ , with a market capitalisation of $602 million . Key value metrics: P/E ratio 29.8, P/B ratio 1.28, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Castle Biosciences, Inc. - Common stock — Fundamental Analysis Summary
Castle Biosciences, Inc. - Common stock (CSTL) is currently trading 28% above its Graham Number of $15.42, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 29.8x.
On financial health, CSTL shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -2.7% (sector average: -20.1%), and minimal leverage with a debt-to-equity ratio of 0.02.
StockPik's composite Value Score for CSTL is 72/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CSTL reports a high gross margin of 77.4% (sector average: 37.4%) and a negative operating margin of -9.1%.
CSTL shows revenue growing at 4% year-over-year, with earnings declining at 232%.